Nizatidine
- Atc Codes:A02BA04
- CAS Codes:76963-41-2
- PHARMGKB ID:76963-41-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Bulgaria: Axid; Cyprus: Axid; France: Nizaxid; Germany: Nizax; Hungary: Naxidin; Ireland: Axid; Italy: Cronizat, Nizax; Luxembourg: Nizaxid, Panaxid; Netherlands: Axid, Nizatidine; Portugal: Nizaxid, Prospaxid; Romania: Nizatidin; UK: Axid.
North America
Canada: Axid, Nizatidine; USA: Axid, Nizatidine.
Latin America
Brazil: Axid.
Asia
Japan: Acinon, Ateminon, Nizamerck, Nizanon, Nizatidine, Nizatin, Nizatiron, Nizatoric, Tizanon.
Drug combinations
Chemistry
Nizatidine: C~12~H~21~N~5~O~2~S~2~. Mw: 331.46. (1) 1,1-Ethenediamine, N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N’-methyl-2-nitro-; (2) N-[2-[[[2-[(Dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N’-methyl-2-nitro-1,1-ethenediamine. CAS-76963-41-2 (1983).
Pharmacologic Category
Other Antihistamines. Antiulcer Agents and Acid Suppressants; Histamine H~2~-Antagonists. (ATC-Code: A02BA04).
Mechanism of action
Competitive inhibition of histamine at H~2~-receptors of gastric parietal cells, resulting in reduced gastric acid secretion, reduced gastric volume and hydrogen ion concentration. In healthy volunteers, nizatidine suppresses gastric acid secretion induced by pentagastrin infusion or food.
Therapeutic use
Treatment and maintenance of duodenal ulcer. Treatment of benign gastric ulcer. Treatment of gastroesophageal reflux disease. Over-the-counter tablet used for prevention of meal-induced heartburn, acid indigestion, and sour stomach.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. Enters breast milk (may be compatible with lactation).
Unlabeled use
Part of multidrug regimen for H. pylori eradication to reduce risk of duodenal ulcer recurrence.
Contraindications
Hypersensitivity to nizatidine or any component of the formulation. Hypersensitivity to other H~2~-antagonists (cross-sensitivity observed).
Warnings and precautions
Relief of symptoms does not preclude presence of gastric malignancy. Use with caution in hepatic and renal impairment.